Literature DB >> 17985418

Predictive markers in rapidly progressing rheumatoid arthritis.

Robert Landewé1.   

Abstract

The emphasis in rheumatoid arthritis (RA) management today is on early diagnosis and intervention, but the choice of intervention has become increasingly complex. The number of disease modifying antirheumatic drugs available for treatment of RA has increased significantly. The efficacy, toxicity, and cost of those agents vary widely. And the progression of joint damage in RA is highly unpredictable and variable, ranging from self-limited disease to rapid progressive destruction. Prognostic markers that could identify patients with aggressive, rapidly progressing disease and predict the response to therapy would provide a rational basis for early, aggressive treatment. They would also protect patients with less aggressive disease from possible overtreatment and toxicities, and could have a significant influence on allocation of healthcare resources. The search for predictive markers of arthritis outcome has been and undoubtedly will continue to be the subject of many studies. This article will review both established and emerging predictive markers in RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985418

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  8 in total

Review 1.  Predicting outcomes in rheumatoid arthritis.

Authors:  Philip G Conaghan
Journal:  Clin Rheumatol       Date:  2011-01-04       Impact factor: 2.980

2.  Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up.

Authors:  Mark Houseman; Catherine Potter; Nicola Marshall; Rachel Lakey; Tim Cawston; Ian Griffiths; Steven Young-Min; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2012-02-07       Impact factor: 5.156

Review 3.  Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Authors:  Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

4.  Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.

Authors:  Fausto Salaffi; Marina Carotti; Alessandro Ciapetti; Stefania Gasparini; Emilio Filippucci; Walter Grassi
Journal:  BMC Musculoskelet Disord       Date:  2011-05-30       Impact factor: 2.362

5.  Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.

Authors:  Mariusz Puszczewicz; Cezary Iwaszkiewicz
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

6.  Novel multiplex technology for diagnostic characterization of rheumatoid arthritis.

Authors:  Piyanka E Chandra; Jeremy Sokolove; Berthold G Hipp; Tamsin M Lindstrom; James T Elder; John D Reveille; Heike Eberl; Ursula Klause; William H Robinson
Journal:  Arthritis Res Ther       Date:  2011-06-24       Impact factor: 5.156

7.  The application of optical coherence tomography in musculoskeletal disease.

Authors:  Christopher Rashidifard; Christopher Vercollone; Scott Martin; Bin Liu; Mark E Brezinski
Journal:  Arthritis       Date:  2013-01-15

8.  Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement.

Authors:  Razvan M Chirila; Florentina Berianu; Andy Abril; Ronald R Butendieck
Journal:  Immun Inflamm Dis       Date:  2021-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.